{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:38Z","timestamp":1791207338548,"version":"4.1.0"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Ras pathway mutations are one of the most common type of alterations in pediatric hematologic malignancies and are frequently associated with adverse outcomes. Despite ongoing efforts to use targeted treatments, there remain no Food and Drug Administration (FDA)-approved medications specifically for children with Ras pathway-mutated leukemia. This review will summarize the role of Ras pathway mutations in pediatric leukemia, discuss the current state of Ras pathway inhibitors and highlight the most promising agents currently being evaluated in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Efficacy using RAF and MEK inhibitors has been demonstrated across multiple solid and brain tumors, and these are now considered standard-of-care for certain tumor types in adults and children. Clinical trials are now testing these medications for the first time in pediatric hematologic disorders, such as acute lymphoblastic leukemia, juvenile myelomonocytic leukemia, and histiocytic disorders. Novel inhibitors of the Ras pathway, including direct RAS inhibitors, are also being tested in clinical trials across a spectrum of pediatric and adult malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Activation of the Ras pathway is a common finding in pediatric hematologic neoplasms. Implementation of precision medicine with a goal of improving outcomes for these patients will require testing of Ras pathway inhibitors in combination with other drugs in the context of current and future clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000000981","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T01:00:20Z","timestamp":1609203620000},"page":"49-58","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Targeting the Ras pathway in pediatric hematologic malignancies"],"prefix":"10.1097","volume":"33","author":[{"given":"Yana","family":"Pikman","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Stieglitz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Benioff Children's Hospital, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat Genet"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bjh.13279","article-title":"Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia","volume":"170","author":"Emerenciano","year":"2015","journal-title":"Br J Haematol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2012.067983","article-title":"Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants","volume":"98","author":"Driessen","year":"2013","journal-title":"Haematologica"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1158\/0008-5472.CAN-08-0101","article-title":"Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia","volume":"68","author":"Case","year":"2008","journal-title":"Cancer Res"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/leu.2016.80","article-title":"The role of the RAS pathway in iAMP21-ALL","volume":"30","author":"Ryan","year":"2016","journal-title":"Leukemia"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/sj.leu.2403641","article-title":"RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia","volume":"19","author":"Wiemels","year":"2005","journal-title":"Leukemia"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/ng.3301","article-title":"The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia","volume":"47","author":"Paulsson","year":"2015","journal-title":"Nat Genet"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/leu.2015.107","article-title":"KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia","volume":"29","author":"Malinowska-Ozdowy","year":"2015","journal-title":"Leukemia"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41467-017-01590-5","article-title":"The genomic landscape of pediatric myelodysplastic syndromes","volume":"8","author":"Schwartz","year":"2017","journal-title":"Nat Commun"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2018-99-116948","article-title":"Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: a report from the LEAP consortium","volume":"132","author":"Pikman","year":"2018","journal-title":"Blood"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1038\/ncomms4469","article-title":"Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia","volume":"5","author":"Mar","year":"2014","journal-title":"Nat Commun"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","article-title":"Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition","volume":"124","author":"Irving","year":"2014","journal-title":"Blood"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"43","DOI":"10.21037\/tp.2019.12.03","article-title":"Mutations predictive of hyperactive Ras signaling correlate with inferior survival across high-risk pediatric acute leukemia","volume":"9","author":"Ney","year":"2020","journal-title":"Transl Pediatr"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-15-1015","article-title":"Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse","volume":"76","author":"Farrar","year":"2016","journal-title":"Cancer Res"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2141.2003.04664.x","article-title":"Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a nonfunctional variant transcript","volume":"123","author":"Ng","year":"2003","journal-title":"Brit J haematol"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1158\/1078-0432.CCR-08-3336","article-title":"Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma","volume":"15","author":"Nojima","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1073\/pnas.87.4.1377","article-title":"FMS mutations in myelodysplastic, leukemic, and normal subjects","volume":"87","author":"Ridge","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0609.2012.01799.x","article-title":"Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement","volume":"89","author":"Arefi","year":"2012","journal-title":"Eur J Haematol"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood-2017-07-798157","article-title":"Integrated molecular profiling of juvenile myelomonocytic leukemia","volume":"131","author":"Murakami","year":"2018","journal-title":"Blood"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41375-019-0549-y","article-title":"Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing","volume":"34","author":"Chao","year":"2020","journal-title":"Leukemia"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/leu.2017.303","article-title":"RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"32","author":"Jerchel","year":"2018","journal-title":"Leukemia"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"26340","DOI":"10.1073\/pnas.2014732117","article-title":"Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A","volume":"117","author":"Bill","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41467-018-04180-1","article-title":"De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia","volume":"9","author":"Hyrenius-Wittsten","year":"2018","journal-title":"Nat Commun"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"21719","DOI":"10.1073\/pnas.1006981107","article-title":"Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia","volume":"107","author":"Paulsson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2014.117424","article-title":"Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high nonresponse and relapse rates","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1002\/cam4.3099","article-title":"High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia","volume":"9","author":"Lee","year":"2020","journal-title":"Cancer Med"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/PAT.0b013e328360b61d","article-title":"Clinicopathological relevance of BRAF mutations in human cancer","volume":"45","author":"Pakneshan","year":"2013","journal-title":"Pathology"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/gcc.22247","article-title":"MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis","volume":"54","author":"Nelson","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"211","author":"Berres","year":"2014","journal-title":"J Exp Med"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.18632\/oncotarget.11730","article-title":"MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations","volume":"8","author":"Kerstjens","year":"2017","journal-title":"Oncotarget"},{"key":"R39-20250730","article-title":"Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia","author":"Loftus","year":"2020","journal-title":"Haematologica"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V120.21.677.677","article-title":"Phase I\/II trial of the MEK1\/2 inhibitor trametinib (GSK1120212) in relapsed\/refractory myeloid malignancies: evidence of activity in patients with RAS mutation-positive disease","volume":"120","author":"Borthakur","year":"2012","journal-title":"Blood"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.3324\/haematol.2014.112995","article-title":"Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance","volume":"100","author":"Ari\u00ebs","year":"2015","journal-title":"Haematologica"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3324\/haematol.2017.185975","article-title":"Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM","volume":"104","author":"Matheson","year":"2019","journal-title":"Haematologica"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13046-018-0820-5","article-title":"Therapeutic potential of combined BRAF\/MEK blockade in BRAF-wild type preclinical tumor models","volume":"37","author":"Del Curatolo","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl J Med"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"e2177","DOI":"10.1038\/cddis.2016.70","article-title":"BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors","volume":"7","author":"Korfi","year":"2016","journal-title":"Cell Death Dis"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc3151","article-title":"Targeting protein prenylation for cancer therapy","volume":"11","author":"Berndt","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.25342","article-title":"Phase II\/III trial of a pretransplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group","volume":"62","author":"Stieglitz","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R54-20250730","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.leukres.2013.12.001","article-title":"Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432","volume":"38","author":"Erba","year":"2014","journal-title":"Leuk Res"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1002\/cncr.33036","article-title":"Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer","volume":"126","author":"Hanna","year":"2020","journal-title":"Cancer"},{"key":"R56-20250730","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-20-1246","article-title":"A phase II trial of tipifarnib for patients with previously treated, metastatic urothelial carcinoma harboring HRAS mutations","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R57-20250730","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nchembio.608","article-title":"Chronicles of the GTPase switch","volume":"7","author":"Cherfils","year":"2011","journal-title":"Nat Chem Biol"},{"key":"R58-20250730","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0968-0896(96)00202-7","article-title":"Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex","volume":"5","author":"Taveras","year":"1997","journal-title":"Bioorg Med Chem"},{"key":"R59-20250730","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"R60-20250730","doi-asserted-by":"crossref","first-page":"101974","DOI":"10.1016\/j.ctrv.2020.101974","article-title":"KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?","volume":"84","author":"Nagasaka","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R61-20250730","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"New Engl J Med"},{"key":"R62-20250730","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"R63-20250730","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1158\/1535-7163.MCT-19-0170","article-title":"Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-mutant cancers","volume":"18","author":"Hao","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"R64-20250730","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41375-018-0020-5","article-title":"Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"R65-20250730","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1535-7163.MCT-18-0852","article-title":"SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors","volume":"18","author":"Lu","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"R66-20250730","article-title":"BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","author":"Hofmann","year":"2020","journal-title":"Cancer Discov"},{"key":"R67-20250730","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R68-20250730","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-13-1978","article-title":"Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia","volume":"20","author":"Konopleva","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R69-20250730","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2014-03-559963","article-title":"The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma","volume":"124","author":"Spencer","year":"2014","journal-title":"Blood"},{"key":"R70-20250730","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26325","article-title":"A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis","volume":"64","author":"Arceci","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R71-20250730","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1535-7163.MCT-17-0456","article-title":"Targeting the MAPK signaling pathway in cancer: promising preclinical activity with the novel selective ERK1\/2 inhibitor BVD-523 (Ulixertinib)","volume":"16","author":"Germann","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"R72-20250730","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:13:31Z","timestamp":1753899211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,29]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000981","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,29]]}}}